IRIS
BERGANTINI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.862
NA - Nord America 4.312
AS - Asia 434
SA - Sud America 16
OC - Oceania 12
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 10.650
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.285
IE - Irlanda 1.560
IT - Italia 1.445
GB - Regno Unito 1.261
SE - Svezia 617
FR - Francia 299
DE - Germania 220
CN - Cina 205
FI - Finlandia 192
UA - Ucraina 103
ES - Italia 92
IN - India 74
VN - Vietnam 64
IR - Iran 28
CA - Canada 26
HK - Hong Kong 16
BE - Belgio 13
AU - Australia 12
TR - Turchia 11
RU - Federazione Russa 8
BR - Brasile 7
CH - Svizzera 7
PL - Polonia 7
EU - Europa 6
NL - Olanda 6
AT - Austria 5
JP - Giappone 5
PK - Pakistan 5
EE - Estonia 4
MK - Macedonia 4
NG - Nigeria 4
PT - Portogallo 4
AR - Argentina 3
CL - Cile 3
PH - Filippine 3
RO - Romania 3
BD - Bangladesh 2
CO - Colombia 2
CY - Cipro 2
EG - Egitto 2
HR - Croazia 2
HU - Ungheria 2
ID - Indonesia 2
JO - Giordania 2
KZ - Kazakistan 2
LT - Lituania 2
QA - Qatar 2
TW - Taiwan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
IL - Israele 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MM - Myanmar 1
MX - Messico 1
MY - Malesia 1
PE - Perù 1
RS - Serbia 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 10.650
Salva come PNG Salva come JPEG
Città #
Dublin 1.532
Southend 1.190
Chandler 641
Fairfield 613
Ashburn 424
Siena 333
Woodbridge 230
Wilmington 223
Houston 212
Seattle 203
Princeton 186
Helsinki 183
Cambridge 179
New York 143
Ann Arbor 127
Florence 107
Shanghai 68
Dong Ket 64
Jacksonville 64
Málaga 64
Fremont 63
Beijing 61
San Mateo 59
Milan 57
San Diego 51
Dearborn 47
Rome 43
Washington 29
Gavirate 24
London 24
Tarazona 17
Boardman 14
Padova 14
Brussels 13
Chicago 13
Hyderabad 13
Toronto 13
Nanjing 12
Zanjan 12
Aachen 11
Naples 11
Chianciano Terme 10
Comun Nuovo 10
Livorno 10
Redwood City 10
Bangalore 9
Grosseto 9
Hong Kong 9
Norwalk 9
Pisa 9
San Francisco 9
Guangzhou 8
Izmir 8
Nanchang 8
Prato 8
Brescia 7
Carrara 7
Chieti 7
Kilburn 7
Leawood 7
Pune 7
Salerno 7
San Casciano in Val di Pesa 7
Bergamo 6
Cagliari 6
Catania 6
Falkenstein 6
Hefei 6
Lappeenranta 6
Paris 6
Rubano 6
Verona 6
Winnipeg 6
Amsterdam 5
Andover 5
Bari 5
Bonndorf 5
Cinisello Balsamo 5
Dallas 5
Gdynia 5
Jinan 5
Mumbai 5
Ponte Buggianese 5
Scandicci 5
Vienna 5
Arese 4
Barcelona 4
Bologna 4
Canberra 4
Fiesole 4
Gunzenhausen 4
Lamézia 4
Maddaloni 4
Melbourne 4
Paglieta 4
Poggibonsi 4
Portogruaro 4
Potenza 4
Rieti 4
Saint-Fons 4
Totale 7.749
Salva come PNG Salva come JPEG
Nome #
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 188
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 185
Peripheral biomarkers' panel for severe COVID-19 patients 176
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 175
null 170
Genetic mechanisms of critical illness in COVID-19 170
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 169
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 158
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 156
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 154
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 152
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 147
NK and NKT-like cells in granulomatous and fibrotic lung diseases 142
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 142
null 134
Serum amyloid A in patients with idiopathic pulmonary fibrosis 131
Prognostic bioindicators in severe COVID-19 patients 130
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 125
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 119
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 119
Immune modulatory effects of novel monoclonal antibodies target therapies in severe eosinophilic asthma patients 118
The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis 116
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 115
null 114
null 113
null 111
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 108
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males. 108
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 107
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 107
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 105
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 105
Serum amyloid A: A potential biomarker of lung disorders 104
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 104
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 101
Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis: What should the rheumatologist do? 100
Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor 99
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 99
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 99
Effects of rituximab therapy on B cell differentiation and depletion 97
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 96
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 93
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 93
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 90
Mapping the human genetic architecture of COVID-19 90
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 89
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 89
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 88
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 88
Serum KL-6 levels in Pulmonary Langerhans' Cell Histiocytosis 86
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy 85
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 84
Pathogen-sugar interactions revealed by universal saturation transfer analysis 82
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 82
Interstitial lung disease associated with psoriatic arthritis: a new disease entity? 82
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 81
WES profiling of COVID-19 81
A first update on mapping the human genetic architecture of COVID-19 80
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 77
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 76
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 76
Immunologic responses to antifibrotic treatment in IPF patients 76
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 76
Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker? 75
null 75
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 74
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 74
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 73
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 72
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 71
Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report 71
Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases 70
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 69
An explainable model of host genetic interactions linked to COVID-19 severity 68
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 68
Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review 68
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study 67
Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases 67
Clinical phenotyping in sarcoidosis management 67
Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab 64
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 62
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 62
null 61
A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists 61
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 60
Serial KL-6 measurements in COVID-19 patients 60
KL-6 in ANCA-Associated Vasculitis Patients with and without ILD: A Machine Learning Approach 60
The Role of Galectins in Chronic Lung Allograft Dysfunction 58
Serum Amyloid A in lung transplantation 57
Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis 57
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 56
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis 56
Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility 55
Multi-Omics Integrative Approach of Extracellular Vesicles: A Future Challenging Milestone 54
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 53
Serial autoantibody detection in interstitial lung diseases: should they be repeated at follow-up? 53
Cytokine profiles in the detection of severe lung involvement in hospitalized patients with COVID-19: The IL-8/IL-32 axis 53
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a New Protocol for Investigating the Mechanisms of Idiopathic Pulmonary Fibrosis 50
High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool? 49
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy 49
Totale 9.431
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.097
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.097
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019135 0 0 0 0 0 0 0 0 0 30 48 57
2019/2020893 47 41 20 94 79 83 85 103 101 98 51 91
2020/20212.166 64 100 101 271 185 246 160 256 217 147 217 202
2021/20222.319 175 263 201 156 112 103 98 109 105 294 266 437
2022/20232.809 181 304 340 279 162 482 292 249 209 123 113 75
2023/20242.807 122 99 331 177 169 704 924 158 44 79 0 0
Totale 11.162